Profil
Jim Wang worked as an Executive Director-Global Regulatory Affairs at Takeda Pharmaceutical Co., Ltd., a Senior Director at Novo Nordisk, Inc., a Manager-Regulatory CMC at Pfizer Inc., and a Vice President & Global Head-Regulatory Strategy at PTC Therapeutics, Inc. He also served as a Vice President at Spark Therapeutics, Inc. Currently, he is working as a Senior Vice President & Head-Regulatory Affairs at Adverum Biotechnologies, Inc. Dr. Wang holds an MBA from The Pennsylvania State University and a doctorate from the University of Illinois.
Anciens postes connus de Jim Wang
| Sociétés | Poste | Fin |
|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Conseiller Juridique Général | 01/08/2023 |
| PFIZER, INC. | Corporate Officer/Principal | - |
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Directeur/Membre du Conseil | - |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | - |
| SPARK THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Formation de Jim Wang
| University of Illinois | Doctorate Degree |
| The Pennsylvania State University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| PTC THERAPEUTICS, INC. | Health Technology |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| PFIZER, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Spark Therapeutics, Inc.
 Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. | Health Technology |
Novo Nordisk, Inc.
Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Health Technology |
